Invesco Galaxy Bitcoin ETF Common Shares of Beneficial Interest (BATS: BTCO)

Dernières nouvelles pour Invesco Galaxy Bitcoin ETF Common Shares of Beneficial Interest (BATS:BTCO)

The Trusts investment objective is to reflect the performance of the spot price of bitcoin as measured using the Lukka Prime Bitcoin Reference Rate (the Benchmark), less the Trusts and other liabilities.

Invesco Galaxy Bitcoin ETF

<a href="https://api.newsfilecorp.com/redirect/PqLMqFAGGe">Kiora Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPRX#NASDAQ">KPRX</a>) today announced it has received a patent (US Patent No. 12,364,680) covering <a href="https://api.newsfilecorp.com/redirect/wEW2EH0JJg">KIO-104</a> for the treatment of a wide range of ocular diseases. This includes, but is not limited to, the following conditions: ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. Additionally, the patent covers varying dosing schedules, necessary excipients, among other novel methods for optimizing treatment of ocular inflammatory diseases. This patent issuance is expected to further strengthen the protection of KIO-104 and extend market exclusivity into 2043.

Biotech

News

General

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection For KIO-104 In The Treatment of Ocular Disease

Contracts

TTEK

Tetra Tech Awarded $10M Contract For Municipal Water Digital Automation Systems

Piper Sandler analyst Ryan Todd downgrades HF Sinclair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>) from Overweight to Neutral and lowers the price target from $53 to $51.

Downgrades

Price Target

Analyst Ratings

DINO

Piper Sandler Downgrades HF Sinclair to Neutral, Lowers Price Target to $51

Northrop Grumman Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) reported second-quarter financial results ahead of the market open on Tuesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/07/g46539738/northrop-grumman-releases-second-quarter-2025-financial-results">from the quarter</a>.
Q2 Earnings: Defense contractor Northrop Grumman reported second-quarter revenue of $10.35 billion, beating analyst <a href="https://www.benzinga.com/quote/NOC/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $10.11 billion, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The company reported second-quarter adjusted earnings of $7.11 per share, beating analyst estimates of $6.76 per share.
Total sales were up 1% on a year-over-year basis and 9% sequentially in the second quarter. Here&#8217;s a breakdown of revenue by category:
<ul class="wp-block-list">
<li>Aeronautics Systems: $3.11 billion, up 2% year-over-year</li>
</ul>
<ul class="wp-block-list">
<li>Defense Systems: $1.99 billion, up 7% year-over-year</li>
</ul>
<ul class="wp-block-list">
<li>Mission Systems: $3.16 billion, up 14% year-over-year</li>
</ul>
<ul class="wp-block-list">
<li>Space Systems: $2.65 billion, down 12% year-over-year</li>
</ul>
Northrop Grumman said operating cash flows decreased $567 million year-over-year and free cash flow declined $468 million, or 42%. The company reported total net awards of $7.4 billion in the quarter. Northrop Grumman ended the period with a total backlog of $89.7 billion. 
"We are working with our customers to accelerate capability delivery to enable their vision of peace through strength. We continue to see growing demand globally for our broad range of product offerings, which resulted in 18% international sales growth in the quarter,&#8221; said Kathy Warden, chair, president and CEO of Northrop Grumman.
Outlook: Northrop Grumman narrowed its 2025 revenue guidance from a range of $42 billion to $42.5 billion to a new range of $42.05 billion to $42.25 billion. The company also raised its 2025 adjusted earnings guidance from a range of $24.95 to $25.35 per share to a new range of $25 to $25.40 per share. Analysts are forecasting full-year revenue of $42.11 billion and earnings of $25.21 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates. 
Northrop Grumman&#8217;s management team will further discuss the quarter on a call with investors and analysts at 9:30 a.m. ET.
NOC Price Action: <a href="http://benzinga.com/quote/NOC">Northrop Grumman shares</a> were up 3.44% at $531.01 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46538453/boeing-737-787-jets-get-green-light-as-air-india-closes-fuel-lock-probe-with-no-issues">Boeing 737, 787 Jets Get Green Light As Air India Closes Fuel Lock Probe With &#8216;No Issues&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/matthew+Munsell">Matthew Munsell</a>/Shutterstock.com

Earnings

Guidance

Movers

Northrop Grumman Q2 Earnings: Revenue, EPS Top Estimates As Global Demand Increases

Wedbush analyst Alicia Reese maintains Logitech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) with a Outperform and raises the price target from $100 to $110.

LOGI

Wedbush Maintains Outperform on Logitech International, Raises Price Target to $110

Citigroup analyst Vikram Bagri maintains Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) with a Neutral and raises the price target from $30 to $68.

OKLO

Citigroup Maintains Neutral on Oklo, Raises Price Target to $68

Wedbush analyst Alicia Reese maintains Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) with a Outperform and raises the price target from $10 to $13.

BYON

Wedbush Maintains Outperform on Beyond, Raises Price Target to $13

D.R. Horton Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) reported third-quarter financial results for fiscal 2025 before the market open on Tuesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/07/b46538721/d-r-horton-inc-americas-builder-reports-fiscal-2025-third-quarter-earnings-and-declares-quarterly-">of the report</a>.
Q3 Earnings: D.R. Horton reported fiscal third-quarter revenue of $9.22 billion, beating analyst <a href="http://benzinga.com/quote/DHI/earnings">estimates</a> of $8.79 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The U.S. homebuilder reported third-quarter earnings of $3.36 per share, beating analyst estimates of $2.92 per share.
Total revenue was down 7% on a year-over-year basis. Home sales revenue also declined 7% to $8.6 billion after the company closed 23,160 homes in the quarter, down 4% year-over-year. Net sales orders came in at 23,071 during the period. 
&#8220;Our net sales orders in the&nbsp;third quarter&nbsp;were flat with the prior year quarter and increased&nbsp;3%&nbsp;sequentially. We closed more homes than the high end of our&nbsp;guidance&nbsp;range, while maintaining a home sales gross margin of&nbsp;21.8%,&#8221; said David Auld, executive chairman of D.R. Horton.
&#8220;Our tenured operators continue to respond to market conditions with discipline to drive traffic and incremental sales, while carefully balancing pace versus price to maximize returns.&#8221;
D.R. Horton said it repurchased 9.7 million shares of its common stock for $1.2 billion in the quarter and returned $122.4 million to shareholders via dividends. The company said it plans to repurchase a total of $4.2 billion to $4.4 billion of its common stock in fiscal 2025. 
Guidance: D.R. Horton narrowed its fiscal 2025 revenue guidance from a range of $33.3 billion to $34.8 billion to a new range of $33.7 billion to $34.2 billion versus estimates of $33.82 billion. 
The company expects to close a total of 85,000 to 85,500 homes during fiscal 2025. 
D.R. Horton executives will provide guidance for the fourth quarter on a conference call, which is set for 8:30 a.m. ET.
DHI Price Action: <a href="http://benzinga.com/quote/DHI">D.R. Horton shares</a> were up 7.5% at $141.11 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46478792/5-homebuilding-stocks-to-considering-selling-on-copper-tariff-threats">5 Homebuilding Stocks To Considering Selling On Copper Tariff Threats</a></li>
</ul>
Photo: JHVEPhoto/Shutterstock.com

D.R. Horton Stock Moves Higher After Homebuilder Beats Q3 Earnings Estimates

NTRP

NextTrip Partners With Jungle Creations To Accelerate Social Growth, Content Engagement, And Brand Awareness Of NextTrip's Travel And Lifestyle Media Brand, JOURNY

Blackstone Makes Majority Growth Investment In NetBrain, Valuing NetBrain At $750M

Citigroup analyst Ronald Josey maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $225 to $265.

AMZN

Citigroup Maintains Buy on Amazon.com, Raises Price Target to $265

Wedbush analyst Alicia Reese reiterates Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Outperform and maintains $210 price target.

Reiteration

Wedbush Reiterates Outperform on Electronic Arts, Maintains $210 Price Target

Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) reported better-than-expected second-quarter financial results and <a href="https://www.benzinga.com/quote/vz/earnings">raised guidance on Monday.</a>
Verizon posted adjusted earnings of $1.22 per share, beating market estimates of $1.19 per share. The company&#8217;s quarterly sales came in at $34.50 billion beating expectations of $33.57 billion.
Total Verizon Business revenues were $7.3 billion, down 0.3% Y/Y. Total Verizon Consumer revenue rose by 6.9% Y/Y to $26.6 billion. Consumer wireless retail postpaid churn was 1.12%, and wireless retail postpaid phone churn was 0.90%.
For FY25, Verizon reiterated a 2.0%-2.8% growth in wireless service revenue. It narrowed its adjusted EPS outlook from $4.59-$4.73 to $4.64-$4.73 versus the consensus of $4.68, driven by demand for its higher-tier plans as per the Reuters report.
Verizon shares gained 4% to close at $42.49 on Monday.
These analysts made changes to their price targets on Verizon following earnings announcement.
<ul class="wp-block-list">
<li>JP Morgan analyst Philip Cusick maintained Verizon with a Neutral and raised the price target from $47 to $49.</li>
<li>Morgan Stanley analyst Benjamin Swinburne maintained the stock with an Equal-Weight rating and raised the price target from $47 to $48.</li>
</ul>
Considering buying VZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/VZ/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22090305/image-308-1024x583.png" alt="" class="wp-image-995410" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22090305/image-308-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22090305/image-308-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22090305/image-308-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22090305/image-308.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46517205/top-2-financial-stocks-that-may-plunge-this-month">Top 2 Financial Stocks That May Plunge This Month</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

These Analysts Raise Their Forecasts On Verizon After Upbeat Q2 Results

Citigroup analyst Tyler Radke maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Buy and raises the price target from $605 to $613.

MSFT

Citigroup Maintains Buy on Microsoft, Raises Price Target to $613

NTHI

NeOnc Technologies Secures Sub-License Deal, Advancing $50M Strategic Partnership With Quazar

LCID

TSLA

Lucid Announces Access To Tesla Supercharger Network Will Be Available For All Lucid Air Models Beginning July 31, With A Lucid-approved Adapter

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is presently trading near our important level of 628.31. Bulls are targeting an initial advance to 629.56. If momentum persists above 629.56, we anticipate buyers driving prices toward our next key support at 631.10. Should buyers confidently defend 631.10 throughout regular session trading, look for a continuation upward to 631.96, with our ultimate bullish target for the day sitting at 632.80.&nbsp;
If bulls lose their grip at 628.31, sellers will aim for downside momentum, initially challenging the 627.25 level. Continued bearish pressure will put the 625.96 mark at risk. Breaking this level decisively could see SPY quickly trading down toward the strong support at 624.22. If selling intensifies dramatically, bears might reach our lowest target for the session at 622.67.
Invesco QQQ Trust Series 1 (QQQ)
The QQQ is currently trading near our pivotal level of 562.78. Bulls must firmly establish price action above this mark, subsequently securing 564.71 as reliable intraday support. Persistent bullish sentiment should then encourage further upside momentum, targeting the next resistance at 567.19. If today&#8217;s buying is robust, anticipate a stretch toward 570.57, with our top bullish objective for the QQQ standing at 573.87.&nbsp;
Should QQQ fail to hold 562.78 convincingly during market hours, bears will seize control and push downward aggressively, first testing the 561.03 area. If weakness persists, expect a deeper selloff toward 559.89. Continued bearish dominance could trigger further downside pressure toward the support at 558.17. A breach here opens the door to our lowest bearish target of the day at 557.16.
Apple Inc. (AAPL)
Apple is trading near our crucial price level of 212.75. Bulls should aim to maintain this support, driving the stock upward initially toward 214.06. Sustained buying could elevate Apple to the next upside hurdle at 215.38. If bullish participants decisively dominate today&#8217;s trading, our high-end bullish target of 217.01 becomes attainable.&nbsp;
If buyers fail to defend the critical level at 212.75, bearish sellers will quickly target 211.75 as their first destination. Continuation of selling momentum would bring Apple down to the next support zone at 210.87. A breakdown of that level might induce additional selling toward 210.12, with further weakness potentially reaching our lower bear target at 209.49.
Microsoft Corp. (MSFT)
Microsoft is currently trading near our highlighted level of 509.09. Bulls will first need to secure the area above 508.79, setting the stage for a move upward toward 510.99, which would then act as an intraday support. Holding firmly above 510.99 would position Microsoft for a bullish run toward 512.86, with sustained buyer participation likely pushing prices to our daily bullish target of 515.30.&nbsp;
If 509.09 is not maintained, expect bears to swiftly challenge the 507.92 mark. Breaking below this support will encourage additional downside pressure, targeting 506.37. Should selling intensify, the next bearish objective becomes 504.85, ultimately opening a path toward our lowest bearish target for the session at 503.48.
NVIDIA Corporation (NVDA)
NVIDIA is currently trading around our critical level of 169.72. Bulls must push the price higher initially to reclaim and firmly establish support at 170.76. Continued upward momentum would then open a pathway to the next resistance point at 172.13. Strong buying throughout the day could drive NVIDIA further upward toward 173.47, with our top bullish target today placed at 175.13.&nbsp;
If NVIDIA cannot hold above 169.72, expect bearish sellers to target a move lower initially toward 167.52. A breakdown here with notable selling volume could rapidly take prices down to 166.01. Further weakening could see bears testing 164.70, and continued downside momentum might ultimately push NVIDIA toward our daily bearish objective at 163.71.
Alphabet Inc Class A (GOOGL)
Alphabet is presently trading close to our significant level of 190.75. Bulls will first aim to firmly secure this area as intraday support, targeting a push higher toward resistance at 191.80. Strong bullish activity might then extend this rally to reach today&#8217;s ultimate bullish target of 193.67.&nbsp;
If buyers are unable to protect 190.75, sellers will likely take control and aggressively test support lower at 189.64. If bearish sentiment intensifies, expect the auction to continue downward toward 188.53. Under heavy selling pressure, Alphabet could fall toward our low-end bearish objective of 186.80.
Meta Platforms Inc (META)
Meta is currently trading near our key level of 714.32. Bulls will look to establish firm price strength above 717.03, setting up the opportunity for further advances toward 718.98. Continued bullish conviction should then lift Meta toward the next resistance level at 721.62, with potential for buyers to drive price action toward our bullish target at 724.27.&nbsp;
If Meta fails to maintain support at 714.32, sellers will immediately target a decline to the support level at 710.41. Continued bearish activity would encourage a further drop toward 707.95. Should this area fail to hold, increased selling might accelerate the move down toward our lowest bearish target of the session at 705.95.
Tesla Inc. (TSLA)
Tesla is currently trading around our significant price level of 328.57. Bulls should first target a move upward to 330.85, with continued buying momentum potentially lifting prices to the next resistance at 334.53. If market sentiment is strongly bullish today, Tesla may push higher toward 340.46, with our maximum bullish objective sitting at 342.71.&nbsp;
If the support level at 328.57 is compromised, anticipate sellers moving swiftly to test lower prices around 326.73. Additional bearish pressure would likely bring Tesla down further to 324.89. Failure at this level with intensified selling could prompt further downside to our daily bearish target of 323.50.
Final Word: Today&#8217;s economic calendar remains exceptionally sparse, continuing the trend of limited catalysts that could keep trading ranges tighter than usual. At 8:30 AM ET, the Philly Fed Non-Manufacturing Activity Index for July will be released, providing regional insights into service sector performance and potential shifts in business sentiment outside manufacturing.&nbsp;
Following at 10:00 AM ET, expect the Richmond Fed Manufacturing Index and Business Conditions report, offering a view into mid-Atlantic factory activity and broader operational trends that might subtly influence economic perceptions.&nbsp;
On the speaker front, Fed Chair Jerome Powell is set to appear at 8:30 AM ET. Given the ongoing blackout period ahead of policy meetings, comments on future rate decisions are improbable, though tensions with the Trump administration could prompt unconventional remarks. Additionally, voting member Fed Governor Michelle Bowman will speak at 1:00 PM ET, potentially touching on key issues without violating blackout norms. Approach the session with measured expectations, monitor for any surprises, and prioritize sound risk management. Good luck and trade safely!
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.
&#x2A;&#x2A;
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

How To Trade SPY, Top Tech Stocks Today Using Technical Analysis

Econ #s

Redbook: US Retail Sales First 2 Weeks Jul +5.2% vs Year Ago

8 analysts have expressed a variety of opinions on Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Jazz Pharmaceuticals, revealing an average target of $176.12, a high estimate of $202.00, and a low estimate of $147.00. Highlighting a 4.67% decrease, the current average has fallen from the previous average price target of $184.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1753189273_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$172.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Jazz Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Jazz Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Unraveling the Financial Story of Jazz Pharmaceuticals</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Jazz Pharmaceuticals's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -0.46% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -10.31%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.24%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.79%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.3, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JAZZ

Where Jazz Pharmaceuticals Stands With Analysts

GM CFO On Conf Call Reportedly Says EV Policy Changes Will Have Minimal Impact on 2025 Results

Invesco Galaxy Bitcoin ETF Common Shares of Beneficial Interest

Invesco Galaxy Bitcoin ETF Beneficial Interest

Comments

Invesco Galaxy Bitcoin ETF Common Shares of Beneficial Interest

Actualités

Dernières nouvelles pour Invesco Galaxy Bitcoin ETF Common Shares of Beneficial Interest (BATS:BTCO)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL